Income Statement
MAXCYTE, INC.
MXCT
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
33.03 | 38.63 | 41.29 | 44.26 | 33.89 |
|
Cost of Revenue
|
6.22 | 7.10 | 4.74 | 5.10 | 3.65 |
|
Gross Profit
|
26.80 | 31.53 | 36.55 | 39.16 | 30.25 |
|
Operating Expenses
|
78.70 | 82.72 | 84.85 | 66.52 | 48.44 |
|
Research & Development
|
20.82 | 22.23 | 23.82 | 19.51 | 15.41 |
|
Selling, General & Administrative
|
28.12 | 29.69 | 30.07 | 25.83 | 18.68 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-51.90 | -51.20 | -48.30 | -27.36 | -18.19 |
|
Non-Operating Income
|
-7.27 | -10.14 | - | - | - |
|
Interest Income
|
7.27 | 10.14 | 10.38 | 3.92 | 0.15 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
7.27 | 10.14 | 10.38 | 3.79 | -0.89 |
|
Income Before Tax
|
-44.63 | -41.06 | - | - | - |
|
Income Tax Expense
|
0.00 | 0.00 | - | - | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-44.63 | -41.06 | -37.92 | -23.57 | -19.08 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-47.67 | -47.05 | -44.31 | -24.83 | -16.84 |
|
Earnings Per Share (Basic)
|
-0.42 | -0.39 | -0.37 | -0.23 | -0.21 |
|
Diluted EPS
|
-0.42 | -0.39 | -0.37 | -0.23 | -0.21 |
|
Weighted Average Shares
|
106.43 | 104.85 | 103.27 | 101.70 | 90.62 |
|
Diluted Weighted Avg Shares
|
106.43 | 104.85 | 103.27 | 101.70 | 90.62 |
|
Comprehensive Income
|
- | - | - | - | - |